Clinical trials: Major Depression
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.
- Trial name
- NCT03864614
- Testing
- SAGE-217
- Where
- 52 sites in United States
- Volunteers
- 1,515 people
- Sponsor
- Biogen
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Depression
Vortioxetine to Prevent Return of Symptoms in Children With Depression
The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.
- Trial name
- NCT05014919
- Testing
- Vortioxetine
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Depression
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
- Trial name
- NCT03378570
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Nicholas Trapp
Dysthymic Disorder, Depressive Disorder NOS
Duloxetine for Chronic Depression: a Double-blind Study
The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major…
- Trial name
- NCT00360724
- Testing
- Duloxetine (Cymbalta)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
To evaluate if somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) obtained with electroencephalography (EEG) and electromyography (EMG) can be used to detect changes in cortical plasticity in responders to…
- Trial name
- NCT01957410
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Janssen Research & Development, LLC
Refractory Major Depressive Disorder
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
- Trial name
- NCT03610048
- Testing
- ALKS 5461
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Alkermes, Inc.
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Depression, Depressive Disorder
Electroacupuncture for Major Depression
This study will compare the safety, efficacy, and tolerability of electroacupuncture (EA) and sham electroacupuncture (SA) for the treatment of major depression.
- Trial name
- NCT00071110
- Testing
- Electroacupuncture
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Unipolar Depression, Bipolar Depression
The Antidepressant Efficacy of the Anticholinergic Scopolamine
A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
- Trial name
- NCT00369915
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
A Study of CX157 (TriRima) for the Treatment of Depression
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD).
- Trial name
- CX157-200 (NCT00739908)
- Testing
- CX157 (TriRima)
- Where
- 14 sites in United States
- Volunteers
- 285 people
- Sponsor
- CeNeRx BioPharma Inc.
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Major
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
- Trial name
- NCT02288325
- Testing
- Levomilnacipran ER
- Where
- 47 sites in United States
- Volunteers
- 644 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Bipolar Disorder
Wake Therapy in the Treatment of Depression
This pilot study seeks to replicate previous findings that sleep deprivation results in marked improvement in depression symptoms, as well as to test whether concurrent treatment with Light Therapy and Lithium are successful in…
- Trial name
- NCT01431573
- Testing
- Wake Therapy, light box, Lithium
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03739203
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 112 sites in United States, Canada and 6 more
- Volunteers
- 752 people
- Sponsor
- AbbVie
Bipolar Disorder
Prevention of Relapse & Recurrence of Bipolar Depression
The purpose of this study is to determine whether the long-term use of combined antidepressant plus mood stabilizer therapy is superior to mood stabilizer therapy alone in preventing the relapse and recurrence of bipolar…
- Trial name
- NCT00961961
- Testing
- Lithium / Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 177 people
- Sponsor
- University of Pennsylvania